In a new paper, researchers from clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine (“Insilico”), in collaboration with NVIDIA, present a new large language model (LLM) transformer for solving biological and chemical tasks called nach0.
MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the
July 25, 2024